Subtype
Autonomic Nervous System Neoplasm
CI-CAN-00000468Explore in graph →
Non-malignant32 active trials3 evidence items
- NCIt
- C5112
Loading cancer entity…
Subtype
CI-CAN-00000468Explore in graph →
Clinical trials
148 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00655655 | Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 96 | Mayo ClinicOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT01999270 | Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors | completed | Phase 1 | 6 | Washington University School of MedicineOTHER | 1 | Oct 21, 2016 | clinicaltrials |
| NCT01204476 |
| Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma |
| completed |
| Phase 1 |
| 27 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Jul 15, 2016 |
| clinicaltrials |
| NCT00458952 | Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma | completed | Phase 1 / Phase 2 | 24 | Molecular Insight Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 13, 2016 | clinicaltrials |
| NCT00049023 | Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors | completed | Phase 1 | 27 | O'Dorisio, M SOTHER | 1 | Jun 21, 2016 | clinicaltrials |
| NCT01155258 | Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors | completed | Phase 1 | 19 | University of Southern CaliforniaOTHER | 1 | Jun 13, 2016 | clinicaltrials |
| NCT01076530 | Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors | completed | Phase 1 | 27 | National Cancer Institute (NCI)NIH | 2 | May 3, 2013 | clinicaltrials |
| NCT00339131 | ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid | completed | Phase 1 | 24 | Molecular Insight Pharmaceuticals, Inc.INDUSTRY | 0 | Oct 12, 2011 | clinicaltrials |
Data updated 22 days agoSource updated Aug 21, 2024source: clinicaltrials